You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

DITROPAN XL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ditropan Xl patents expire, and when can generic versions of Ditropan Xl launch?

Ditropan Xl is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in DITROPAN XL is oxybutynin chloride. There are sixteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ditropan Xl

A generic version of DITROPAN XL was approved as oxybutynin chloride by TEVA PHARMS USA on November 14th, 1988.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DITROPAN XL?
  • What are the global sales for DITROPAN XL?
  • What is Average Wholesale Price for DITROPAN XL?
Drug patent expirations by year for DITROPAN XL
Drug Prices for DITROPAN XL

See drug prices for DITROPAN XL

Recent Clinical Trials for DITROPAN XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Il-Yang Pharm. Co., Ltd.Phase 2
Seoul National University HospitalPhase 2
Brigham and Women's HospitalPhase 2

See all DITROPAN XL clinical trials

US Patents and Regulatory Information for DITROPAN XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-001 Dec 16, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-002 Dec 16, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-003 Jun 22, 1999 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DITROPAN XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-002 Dec 16, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-002 Dec 16, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-002 Dec 16, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-001 Dec 16, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-003 Jun 22, 1999 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms DITROPAN XL oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 020897-002 Dec 16, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DITROPAN XL

See the table below for patents covering DITROPAN XL around the world.

Country Patent Number Title Estimated Expiration
Japan 2007197462 DOSAGE FORM COMPRISING OXYBUTYNIN ⤷  Sign Up
Switzerland 669329 ⤷  Sign Up
Italy TO960427 ⤷  Sign Up
Sweden 8402512 ⤷  Sign Up
Canada 1222950 DISPOSITIF OSMOTIQUE A DOUBLE ACTIVITE THERMODYNAMIQUE (OSMOTIC DEVICE WITH DUAL THERMODYNAMIC ACTIVITY) ⤷  Sign Up
South Africa 8402422 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.